Acyclic nucleoside phosphonates (ANPs) play a key role in the treatment of a variety of infectious diseases including antiviral, antiparasitic, antimicrobial and antituberculotic conditions. Unfortunately, ANPs suffer of poor bioavailability due to the presence of an ionized phosphonic acid group. To circumvent this problem several prodrugs strategies have been evaluated. Among them, the ProTide approach have proved to be one of the most powerful technology with the phosphonoamidate tenofovir alafenamide fumarate (TAF, Vemlidy) approved in 2015 for the treatment of HIV and later in 2016 for HBV infections. Given the tremendous importance of phosphonoamidate prodrugs in the antiviral arena and beyond, the two synthetic methodologies to prepare ProTides of alkenyl ANPs, reported in this unit, are of extremely importance for the drug development of this class of compounds.
INTRODUCTION
This unit presents two different synthetic strategies for the synthesis of alkenyl acyclic nucleoside phosphonoamidate prodrugs. The first methodology (Basic Protocol 1) consists in the preparation of linear (E)-but-2-enyl pyrimidine ProTide via the bis trimethylsilyl ester of the parent alkenyl dimethylphosphonate nucleoside, synthetized following the procedure reported in Basic protocol 1 Unit 14.11 (Bessières et al., 2001) . This intermediate, obtained by treatment of the parent nucleoside with an excess of trimethylsilyl bromide (TMSBr) is reacted, without purification, with the desired amino acid ester and an excess of phenol in pyridine in the presence of triethylamine, aldrithiol-2 and triphenylphosphine.
The procedure reported in Basic Protocol 2 involves in the first instance, the preparation of the allylphosphonoamidate intermediate obtained in the same way as in the Basic Protocol 1. This derivative is then reacted with alkylated nucleobase via olefin cross metathesis using second generation Hoveyda-Grubbs catalyst to obtain the branched (E)-2-methyl-but-2-enyl pyrimidine ProTide.
NOTE: All glassware should be oven dried, and all reactions should be performed under anhydrous conditions. CAUTION: All reactions must be run in a suitable fume hood with efficient ventilation. Safety glasses and reagent-impermeable protective gloves should be worn at all time.
Compound characterization. Chemical characterizations data are provided for all compounds. 1 H, 31 P and 13 C NMR spectra were recorded in a Bruker Avance 500 spectrometer at 500 MHz, 202 MHz and 125 MHz respectively and auto-calibrated to the deuterated solvent reference peak in case of 1 H and 13 C NMR and 85% H3PO4 for 31 P NMR experiments. All 31 P and 13 C NMR spectra were proton-decoupled.
Chemical shifts are given in parts per million (ppm) and coupling constants (J) are measured in Hertz (Hz) and related to multiplicities. Analytical High Performance Liquid Chromatography (HPLC) analysis was performed using Varian Prostar system (LC-Workstation-Varian Prostar 335 LC detector). High resolution mass spectrometry was performed on a Bruker Daltonics MicroTof-LC system (atmospheric pressure ionization, electron spray mass spectroscopy) in positive mode.
BASIC PROTOCOL 1 PREPARATION OF (E)-BUT-2-ENYL PHOSPHONOAMIDATE PYRIMIDINE
The synthesis of phosphonodiamidate prodrugs of ANPs via bis trimethylsilyl ester has been reported by Holy et al (Jansa et al., 2011) and then successfully adapted by us for the synthesis of adefovir and tenofovir phosphonoamidate prodrugs . In this protocol we are reporting a modification of this methodology (Pertusati et al., 2017) for the synthesis of SP and RP isomers of (E)-N 1 -(4'-O-phenyl-(neopentyloxy-L-alanine)-phosphinyl-but-2-enyl)thymine (3a and 3b). (E)-N 1 -(4'dimethoxyphosphinyl-2'-butenyl) thymine (1), prepared according to literature procedures (Topalis et al., 2011) , is reacted overnight with TMSBr at room temperature to afford intermediate 2, which after removal of the volatile is used in the next step without further purification. The mixture of diastereoisomers 3a and 3b is obtained by stirring 2 with the desired amino acid ester salt and an excess of phenol in presence of aldrithiol-2 and triphenylphosphine at 50 o C for 16 h. Purification by flash chromatography, followed by preparative HPLC, allows the separation of the two diastereoisomers (3a and 3b).
Figure 1.
Synthesis of SP and RP isomer of (E)-N 1 -(4'-O-phenyl-(neopentyloxy-L-alanine)phosphinyl-but-2-enyl)thymine (3a and 3b). (1H, d, J=1.1 Hz, m, m, m, NCH2CH= and =CHCH2P), 4.35 (2H, m, CH2N), 3.91, 3.82 (2H, AB, JAB = 10.5 Hz, CH2C(CH3) 
Materials
(E)-N 1 -(4'-dimethoxyphosphinyl-2'-butenyl)(E)-N 1 -(4'-O-phenyl-(neopentyloxy-L-alanine)-phosphinyl-but-2-enyl)thymine (3aand
BASIC PROTOCOL 2 PREPARATION OF (E)-2-METHYL-BUT-2-ENYL PHOSPHONOAMIDATE PYRIMIDINE
This protocol describes the preparation of phosphonoamidate prodrugs of trisubstituted alkenyl acyclonucleoside using cross-metathesis reaction. Olefin crossmetathesis methodology has been used for the direct synthesis of a vast array of unsaturated ANPs analogues including bis-POM, bis-POC, and alkoxyesters prodrugs (Hamada et al., 2013; Pradère et al., 2011) . Only very recent application of such procedure for the preparation of ProTides has been reported (Bessières et al., 2018) .
Despite some similarities, the synthetic strategy we are reporting here differs from that published by Agrofoglio et al.
This methodology involves first the synthesis of the aryloxy allylphosphonoamidate 6
as the key synthon. Briefly, the commercial dimethyl allylphosphonate 4 is converted into the corresponding silyl ester 5 in presence of an excess of TMSBr and 2,6lutidine as acid scavenger. After removal of the volatile 5 is used without further purification and treated with the amino acid ester hydrochloride and an excess of aryl alcohol in presence of aldrithiol-2 and triphenylphosphine at 50 o C for 16 h to obtain the desired allylphosphonoamidate 6.
The second olefin partner for the cross metathesis reaction (9 and 10) was synthesized by N 1 -substitution using 3-bromo-2-methylpropene (Bessieres et al., 2016) .
As illustrated in Figure 2 , the allylphosphonoamidate intermediate 6 is then sonicated with 2-methylallyl pyrimidines 9 and 10 in presence of Hoveyda-Grubbs second generation catalyst in CH2Cl2 at reflux for 24 h, to obtain the final ProTides 11 and 12. (6) as key synthon.
Materials
Dimethyl allylphosphonate (4) 6. Dissolve the solid in 10 mL of anhydrous pyridine under an argon atmosphere.
7. Add 0.558 g (3.3 mmol) of dry L-alanine isopropyl ester hydrochloride, 2.88 g (19.9 mmol) of dry 1-naphthol and 6.9 mL (49.9 mmol) of triethylamine.
8. Place the reaction mixture in an oil bath, heat at 50 ˚C and stir for 10 min to obtain a yellow solution.
9. Prepare a solution with 4.40 g (19.9 mmol) of aldrithiol-2 and 5.24 g (19.9 mmol) of triphenylphosphine in 10 mL of anhydrous pyridine under an argon atmosphere. 
Purify the residue by Biotage Isolera One
Dissolve the crude product in the minimum amount of CH2Cl2 and carefully place into a 50 g SNAP cartridge ULTRA. Purify using a 100 ml/min gradient eluent system EtOAc/hexane 17% 1CV, 17-100% 10CV, 100% 3CV.
Monitor the fractions by TLC and visualize by UV light, combine the fractions
containing the pure product and evaporate to dryness using a rotary evaporator under reduced pressure to afford compounds 9 and 10 as pale-yellow solids.
28. Characterise the compounds by 1 H NMR.
N 1 -2 '-methylallyl-uracil (9) . Yield 1.2 g (51%) . . 1 H NMR (500 MHz, CD3OD) δH: 7.50 (d, J = 7.8 Hz, 1H, 5.71 (d, J = 7.8 Hz, 1H, 4.98 (s, 1H, CH2=), 4.81 (s, 1H, CH2=), 4.33 (s, 2H, 1.76 (s, 3H, CH3, alkene) . N 1 -2'-methylallyl-thymine (10). Yield 2.1 g (98%). . 1 H NMR (500 MHz, CD3OD) δH: 7.34 (s, 1H, 4.98 (s, 1H, CH2=), 4.80 (s, 1H, CH2=), 4.30 (s, 2H, 1.89 (s, 3H, CH3, base), 1.76 (s, 3H, CH3, alkene) . 31 P NMR spectra documented below were obtained with proton decoupling. Yield 0.028 g (14%) . . 31 P NMR (202 MHz, CD3OD) δP: 30.28, 29.49. 1 H NMR (500 MHz, 1H, ArH), 1H, ArH), 1H, ArH), 3H, ArH), 2H, ArH), 1.5H, CH=, 0.5H, CH=), 4.93 (sept, J = 6.5 Hz, 0.5H, CH(CH3) 2), 4. 0.5H, CH(CH3) 2), 4. 2H,  1H, CHCH3 L-Ala), 3.08-2. 90 (m, 2H, CH2P), 1.65 (bs, 3H, CH3, alkene Hz, CH3, alkene), 13.2 (d, CH3, alkene) .
HPLC: Reverse phase HPLC eluting with gradient method CH3CN/H2O from 10/90 to 100/0 in 30 minutes, 1ml/min, λ = 254 nm and 263 nm, showed one peak with tR 15.57 min. C25H30N3O6P: 522.1770, found: 522.1764 . Yield 0.075 g (36%) . . 31 P NMR (202 MHz, CD3OD) δP: 30.32, 29.54. 1 H NMR (500 MHz, 1H, ArH), 1H, ArH), 1H, ArH), 3H, ArH), 1H, ArH), 7.27 (s, 0.5H, 7.26 (s, 0.5H, 1H, CH=), 1H, CH(CH3)2), 2H, 1H, 2H, CH2P), 1.75 (s, 3H, CH3, base), 1.67 (s, 3H, CH3, alkene), 1.27 (d, J = 6.9 Hz, 1.5H, CHCH3 L-Ala), 1. 4.5H, CH(CH3) 2), 1. 3H, CH(CH3) 2). 13 C NMR (125 MHz, CD3OD) δC: 173.5 (d, C=O, ester), 173.1 (d, C=O, ester), 146.5 (d, Ph), 146.3 (d, Ph), 135.5 (d, C=), 135.1 (d, C=), 126.7 (d, 126.6 (d, CH=), CH=), 115.3 (d, 115.1 (d, 68.69 (CH(CH3) 2), 68.65 (CH(CH3)2), 53.5 (d, 53.2 (d, 4 (CH3) 2), 20.40 (CH(CH3)2), 19.8 (d, 19.1 (d, 13.3 (d, CH3, alkene), 13.2 (d, CH3, alkene), 10.8 (CH3, base) .
HRMS (ESI): m/z [M+Na] + calcd for
HPLC: Reverse phase HPLC eluting with gradient method CH3CN/H2O from 10/90 to 100/0 in 30 minutes, 1ml/min, λ = 254 nm and 263 nm, showed one peak with tR 16.26 min. C26H32N3O6P: 536.1926, found: 536.1921 .

COMMENTARY
Background Information
In the last years, the ProTide approach, pioneered by Chris Mcguigan's group, has displayed a great deal of success in the development of nucleoside-based antivirals and anticancer drugs. Sofosbuvir (Nakamura et al., 2016) and TAF (Abdul Basit et al., 2017; Ray et al., 2016) on the market for viral infections, and Acelerin (Slusarczyk et al., 2014) We were able to synthetize prodrugs of adefovir and tenofovir in moderate yield by adaption of the one-pot procedure for preparing phosphonodiamidate, reported by Jansa et al 2011 (Jansa et al., 2011) . Unfortunately, when these conditions were applied on the alkenyl-pyrimidine substrate, only traces of the desired phosphonoamidate product were detected with the phosphonodiamidate being the major product. Increasing the equivalents of the aryl-alcohol (6 equivalents) with respect to the amino acid (1 equivalent) proved necessary to obtain the desired phosphonoamidate in moderate yield as reported in Basic Protocol 1 for the preparation of linear (E)-4-phosphonoamidate-but-2'en-1'-yl pyrimidine (Pertusati et al., 2017) . However, we discovered that this methodology suffers from the limitation that only linear olefin must be employed, as with trisubstituted alkenyl derivatives no formation of the desired ProTide was observed in our hand. This finding prompted us to investigate and then develop the methodology reported in Basic Protocol 2 using a cross-metathesis reaction for the direct synthesis of branched unsaturated ANP phosphonoamidates. At the time we started this investigation, no application of such procedure for the synthesis of ProTides was yet reported. However, recently, a paper reporting on the use of the cross metathesis for the synthesis of ProTide derivatives of linear (E)-but-2-enyl nucleoside scaffold, was published by Agrofoglio et al. (Bessières et al., 2018) Both our and Agrofofoglio's procedures involves the preparation of the aryl allylphosphonoamidate intermediate to be then reacted with the alkylated nucleobase in the CM reaction. However our synthetic pathway using the one-pot procedure reported by Holi (Jansa et al., 2011) proves to be a shorter and efficient approach for the synthesis of the allylphosphonoamidate synthon. Moreover the cross metathesis conditions appear to be different. Dichloromethane was the solvent of choice in our case with branched alkenyl nucleosides whereas for Agrofoglio linear olefin only water was effective.
Critical Parameters and Troubleshooting
The successful preparation of the silylated intermediates 2 and 5 in both Basic Protocol 1 and 2 is critical for the outcome of the two synthetic procedures. In particular, timing (16 h) is a crucial parameter for this step as in case of too short reaction time only partial dealkylation can be observed. The silyl esters 2 and 5 are air and moisture sensitive compounds and therefore must be kept at all the time under strictly dry atmosphere.
For Basic Protocol 2, the presence of 2,6-lutidine revealed to be essential for the first step as only degradation of the silyl ester intermediate 5 is detected when this acid scavenger in not present.
For the preparation of the aryl phosphonoamidate moiety (ProTide approach) in both Basic Protocols 1 and 2, the aryl-alcohol to amino acid ester ratio needs to be 6 to1 in favor of the aryloxy reagent to reduce the formation of the bisamidate derivative as byproduct. For the cross metathesis reaction, the sequential catalyst loading is a crucial parameter to afford the desired transalkylidenation product in good yield.
The synthetic procedures described in this unit are intended for use only by persons with prior training in experimental organic chemistry and thus with knowledge of the common chemical laboratory techniques, such as extraction, solvent evaporation, column chromatography, TLC and HPLC. Characterization of the products demands knowledge of monodimensional ( 1 H, 13 C and 31 P) and bidimensional (COSY, HSQC, HMBC and NOESY) NMR experiments, as well as of mass spectroscopy. Careful attention to details of basic organic synthesis methodologies is required. General laboratory safety is also of primary concern when hazardous materials are involved.
Strict adherence to the reported procedures is therefore highly recommended.
Understanding Result
The approaches applied in both Basic protocol 1 and 2 can be applied to prepare numerous alkenyl acyclic pyrimidine ProTide derivatives with different aryloxy and amino acid ester moieties. Moreover, both the protocols can be adapted to obtain the bis-amidate derivatives when in the first step of the two methodologies only the amino acid ester is employed.
The cross metathesis reaction can be significant influenced by the length of the acyclic side chain. When the CM procedure reported in Basic Protocol 2 is employed for the preparation of aryl vinylphosphonoamidate derivatives, no formation of the final product is observed.
Time Considerations
According to Basic Protocol 1, two weeks are required for the nucleoside preparation including purification and characterization of the final ProTide. In case of Basic Protocol 2 only one week is needed for the synthesis, characterization of the phosphonoamidate prodrug including the preparation of the two olefins and the cross metathesis reaction.
